What is Avoro Capital Advisors buying in Q2 2026?
In Q2 2026, Avoro Capital Advisors opened 2 new biotech positions, exited 53, added to 10 existing holdings — its largest new buy was COAG at $70.7M.
See Avoro Capital Advisors’s full 13F →Q2 2026 · 20 specialist funds · parsed from SEC 13F filings
Biotech Smart Money Moves
What are biotech's best-informed investors buying and selling? Every quarter we parse the 13F filings of 20 specialist biotech hedge funds and surface the conviction moves: 139 new positions and 1680 full exits in Q2 2026.
Top new buys in Q2 2026
The largest new biotech positions initiated by specialist funds this quarter, ranked by reported position value.
Biggest exits in Q2 2026
Positions specialist funds sold out of completely this quarter, ranked by last reported value.
Track smart money as it files
New 13F positions and exits from 20 specialist biotech funds — free every Monday.
What each fund is buying and selling
A one-line read on every tracked fund's Q2 2026 activity, with its top moves.
What is Baker Bros. Advisors buying in Q2 2026?
In Q2 2026, Baker Bros. Advisors opened 6 new biotech positions, exited 70, added to 11 existing holdings — its largest new buy was SNSE at $32.2M.
- RVMDIncreased$2.1B
What is Boxer Capital buying in Q2 2026?
In Q2 2026, Boxer Capital made no material biotech moves.
No material biotech moves filed this quarter.
See Boxer Capital’s full 13F →What is BVF Partners buying in Q2 2026?
In Q2 2026, BVF Partners opened 4 new biotech positions, exited 42, added to 6 existing holdings — its largest new buy was QTTB at $29.9M.
See BVF Partners’s full 13F →What is Casdin Capital buying in Q2 2026?
In Q2 2026, Casdin Capital opened 5 new biotech positions, exited 36, added to 10 existing holdings — its largest new buy was PBLS at $17.7M.
See Casdin Capital’s full 13F →What is Commodore Capital buying in Q2 2026?
In Q2 2026, Commodore Capital opened 2 new biotech positions, exited 59, added to 8 existing holdings — its largest new buy was EDIT at $28.8M.
See Commodore Capital’s full 13F →What is Cormorant Asset Management buying in Q2 2026?
In Q2 2026, Cormorant Asset Management opened 9 new biotech positions, exited 71, added to 6 existing holdings — its largest new buy was PBLS at $126.3M.
See Cormorant Asset Management’s full 13F →What is Deep Track Capital buying in Q2 2026?
In Q2 2026, Deep Track Capital opened 12 new biotech positions, exited 97, added to 26 existing holdings — its largest new buy was COAG at $132.3M.
See Deep Track Capital’s full 13F →What is Deerfield Management buying in Q2 2026?
In Q2 2026, Deerfield Management opened 7 new biotech positions, exited 254, added to 15 existing holdings — its largest new buy was PBLS at $51.5M.
See Deerfield Management’s full 13F →What is Driehaus Capital buying in Q2 2026?
In Q2 2026, Driehaus Capital opened 8 new biotech positions, exited 120, added to 49 existing holdings — its largest new buy was CLDX at $36.8M.
See Driehaus Capital’s full 13F →What is EcoR1 Capital buying in Q2 2026?
In Q2 2026, EcoR1 Capital opened 8 new biotech positions, exited 87, added to 4 existing holdings — its largest new buy was FULC at $24.0M.
See EcoR1 Capital’s full 13F →What is Eventide Asset Management buying in Q2 2026?
In Q2 2026, Eventide Asset Management opened 13 new biotech positions, exited 83, added to 28 existing holdings — its largest new buy was AVLN at $45.3M.
See Eventide Asset Management’s full 13F →What is Foresite Capital buying in Q2 2026?
In Q2 2026, Foresite Capital opened 1 new biotech position, exited 10, added to 2 existing holdings — its largest new buy was CRNX at $5.6M.
See Foresite Capital’s full 13F →What is OrbiMed Advisors buying in Q2 2026?
In Q2 2026, OrbiMed Advisors opened 15 new biotech positions, exited 109, added to 43 existing holdings — its largest new buy was ODTX at $56.2M.
See OrbiMed Advisors’s full 13F →What is Perceptive Advisors buying in Q2 2026?
In Q2 2026, Perceptive Advisors opened 9 new biotech positions, exited 129, added to 35 existing holdings — its largest new buy was KARD at $195.6M.
See Perceptive Advisors’s full 13F →What is RA Capital Management buying in Q2 2026?
In Q2 2026, RA Capital Management opened 14 new biotech positions, exited 91, added to 9 existing holdings — its largest new buy was PBLS at $791.9M.
- PBLSNew Position$791.9M
- EWTXTrimmed$341.0M
- NAMSWTrimmed$323.7M
- COAGNew Position$286.8M
- GHRSTrimmed$205.3M
What is Redmile Group buying in Q2 2026?
In Q2 2026, Redmile Group opened 4 new biotech positions, exited 55, added to 5 existing holdings — its largest new buy was CLYM at $16.0M.
See Redmile Group’s full 13F →What is Rock Springs Capital buying in Q2 2026?
In Q2 2026, Rock Springs Capital opened 12 new biotech positions, exited 80, added to 33 existing holdings — its largest new buy was AVLN at $21.8M.
See Rock Springs Capital’s full 13F →What is RTW Investments buying in Q2 2026?
In Q2 2026, RTW Investments opened 5 new biotech positions, exited 74, added to 25 existing holdings — its largest new buy was KLRA at $237.4M.
See RTW Investments’s full 13F →What is Tang Capital Management buying in Q2 2026?
In Q2 2026, Tang Capital Management opened 3 new biotech positions, exited 160, added to 6 existing holdings — its largest new buy was NVCT at $28.5M.
See Tang Capital Management’s full 13F →How smart-money tracking works
What is smart money in biotech?
Smart money refers to the specialist hedge funds that focus exclusively on biotech — the investors with deep scientific diligence teams and industry networks. We track 20 of them and parse their SEC 13F filings every quarter to surface where they're putting capital to work.
What does a new 13F position tell you?
A new position means a fund initiated a holding it didn't own last quarter — an active portfolio decision, not drift. New positions and full exits are the strongest signals in 13F data because they represent conviction-level moves that often take months to build.
How fresh is 13F data?
13F filings are due within 45 days of quarter-end, so the data reflects positions as of the prior quarter-end, not today. Despite the lag, it reveals the conviction decisions of biotech's most informed investors — positions that took months to accumulate.
Which funds do you track?
We track 20 specialist biotech hedge funds, including firms like Baker Bros. Advisors, Perceptive Advisors, OrbiMed, and RTW Investments. See the fund index for the full list with per-fund 13F histories.
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →